[Clinical evaluation of GV-523 for severe infections complicating hematopoietic diseases--a comparative study using the cross-over method. Hematopoietic Disease Study Group for GV-523].
T
T
Masaoka
H
H
Shibata
K
K
Nagai
A
A
Kanamaru
T
T
Yonezawa
Y
Y
Kanayama
T
T
Kitani
N
N
Taniguchi
A
A
Horiuchi
H
H
Hasegawa
D000293:Adolescent; D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D004338:Drug Combinations / Q000008:administration & dosage; D005260:Female; D005341:Fibrinolysin / Q000008:administration & dosage*; D006402:Hematologic Diseases / Q000150:complications*; D006801:Humans; D016756:Immunoglobulins, Intravenous; D007239:Infections / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D018805:Sepsis / Q000628:therapy; D005719:gamma-Globulins / Q000008:administration & dosage*
D004338:Drug Combinations; D016756:Immunoglobulins, Intravenous; D005719:gamma-Globulins; D005341:Fibrinolysin